Global /South Korea /Healthcare /Drug Manufacturers - General /018680
chevron_leftBack
Seoul Pharma Co., Ltd. logo

Seoul Pharma Co., Ltd.

018680
KRX: 018680 Delayed
2,790KRW -1.9%
1.84 USD
As of 14 June 2026, Seoul Pharma Co., Ltd. has a market cap of $21.77M USD, ranking #36518 globally and #2304 in South Korea. It ranks #3280 in the Healthcare sector, and #1098 in the Drug Manufacturers - General industry.
Global Rank
36518
Country Rank
2304
Sector Rank
3280
Industry Rank
1098
Key Stats
Market Cap
$21.77MUSD
33.11B KRW
Enterprise Value
$26.71MUSD
40.56B KRW
Revenue (TTM)
$34.29MUSD
52.15B KRW
EBITDA (TTM)
$910.74KUSD
1.38B KRW
Net Income (TTM)
$495.55KUSD
753.64M KRW
EBITDA Margin
2.7%
Profit Margin
1.4%
PE Ratio
43.9
PS Ratio
0.6
PB Ratio
0.8
EV/EBITDA
29.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Hei Youn Hwang open_in_new
Employees
172
Founded
1976
Website
seoulpharma.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-1.9% -1.6% 4.6% -3.7% -10% -16%

News

Loading...

Markets

Exchange Ticker Price
Korea Exchange
MIC: XKRX
PRIMARY
018680
(주)서울제약
ISIN: KR7018680009
Shares Out.:
11.659M1 Shares Float: 7.868M2
TV:
SA:
YF:
GF:
BA:
MS:
2,790 KRW
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Seoul Pharma Co., Ltd.

Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer’ disease; OBCARE to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency; and CH.V, as well as products for schizophrenia, vitamin supplement, obesity, tonic, and menopausal syndrome. The company also provides Ator for high blood pressure treatment; Flavel to treat stroke; Axated, a peptic ulcer medication; Crestin to treat hyperlipidemia; and Weltmin and Fendigene for the treatment of obesity. It also owns patents to orally dispersible films. The company was founded in 1976 and is headquartered in Cheongju-si, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)
Name
Market Cap diff.
PE
$9.15B
13.91T KRW
42K%
-
$6.77B
10.3T KRW
31K%
1958.1
$5.24B
7.97T KRW
24K%
29.9
298380
$4.96B
7.55T KRW
23K%
-
000100
$4.55B
6.92T KRW
21K%
35.9
$4.44B
6.76T KRW
20K%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
3M%
38.1
JNJ
$547.28B
3M%
26.4
ABBV
$360.63B
2M%
97.4
$321.52B
256.25B CHF
1M%
19.9
AZN
$288.84B
215.59B GBP
1M%
27.6
NOVN
$274.65B
218.9B CHF
1M%
20.5
chevron_leftBack